Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy

Sponsor
Innocoll (Industry)
Overall Status
Completed
CT.gov ID
NCT00749749
Collaborator
Premier Research Group plc (Industry)
27
1
2
3.4
8

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System.

Condition or Disease Intervention/Treatment Phase
  • Drug: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
  • Drug: ON-Q PainBuster Post-op Pain relief System
Phase 2

Detailed Description

Hysterectomy is the second most common surgery among women in the United States (US). Abdominal hysterectomy surgery may be performed to treat benign tumors, such as fibroids, heavy periods, painful periods and chronic pelvic pain. The most common route for performing hysterectomy is through an incision in the abdominal wall; however, about 20% are performed vaginally.Laparoscopic assisted vaginal hysterectomy is performed when warranted.

Bupivacaine is a local anesthetic (pain medication) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cattle tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.

The ON Q system consists of 1 elastometric pump with a fill volume of 270 mL containing 0.25% bupivacaine; 1 soaker catheter measuring 12.5 cm in size; and a fill port, tubing, clamp, filter and flow restrictor. The pump provides positive pressure and is portable. It may be attached to the patient's dressing or placed in a carrying pouch. The catheter is inserted directly into the surgical wound providing a continuous flow of bupivacaine into the wound. A capillary flow restricting orifice located at the end of the tubing controls the flow rate.

This study will compare the total narcotic use in patients with the CollaRx Bupivacaine Implant with the total narcotic use in patients with the ON Q PainBuster Post op Pain Relief System after abdominal hysterectomy.

Study Design

Study Type:
Interventional
Actual Enrollment :
27 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II, Randomized, Single-dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy
Study Start Date :
Sep 10, 2008
Actual Primary Completion Date :
Dec 22, 2008
Actual Study Completion Date :
Dec 22, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bupivacaine collagen sponge

Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.

Drug: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
Other Names:
  • CollRx Bupivacaine Implant
  • Active Comparator: ON-ON-Q PainBuster Post-op Pain relief SystemQ system

    Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.

    Drug: ON-Q PainBuster Post-op Pain relief System
    5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])

    Outcome Measures

    Primary Outcome Measures

    1. Total Amount of Opioid Rescue Analgesia Used [0 to 24 hours postoperatively]

      Higher value means worse outcome - Higher number reflects a need for more analgesia - For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. Measurement recorded in total Morphine Milligrams

    Secondary Outcome Measures

    1. Total Amount of Opioid Rescue Analgesia Used [0 to 48 hours postoperatively]

      Higher score means worse outcome - Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.

    2. The Total Amount of Opioid Rescue Analgesia Used [0 to 96 hours postoperatively]

      Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.

    3. Total Use of Opioid Rescue Analgesia (mg) Over 0 to 72 Hours [0 to 72 Hours]

      Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.

    4. Time to First Use of Opioid Rescue Analgesia [0 to 72 hours]

      Higher score has a better outcome

    5. VAS Pain Intensity Scores Over Time AT REST [Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96]

      For the VAS assessment, patients measured their pain intensity at rest using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.

    6. VAS (mm) Pain Intensity Scores Over Time (After Cough) [Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96]

      For the VAS assessment, patients measured their pain intensity after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Must be a woman who is ≥ 18 and ≤ 75 years of age.

    • Has a body mass index (BMI) > 19 and < 40 kg/m2.

    • Has planned an elective total abdominal hysterectomy for reasons other than malignancies (such as uterine adenocarcinoma, cervical cancer or leiomyosarcoma) to be performed according to standard surgical technique using a standard incision and under general anesthesia with the following caveats:

    • Laparoscopic procedures or supraumbilical or Maylard incisions will not be allowed.

    • A nonlaparoscopic incision for benign nonhysterectomy gynecological procedures (such as myomectomy or adnexal surgery) is acceptable if the surgical indication is not to treat pelvic pain.

    • No concomitant vaginal procedures such as anterior and posterior colporrhaphy (A&P repairs) are allowed. An abdominal urethropexy and an incidental appendectomy will be allowed.

    • Has a risk classification of I, II or III according to the American Society of Anesthesiologists (ASA).

    • Is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and nonlactating.

    • Is free of other physical or mental conditions that, in the opinion of the Investigator, may confound quantification of postoperative pain resulting from the abdominal hysterectomy.

    • Has the ability to read, understand and comply with the study procedures and the use of the pain scales; is deemed capable of operating a patient controlled analgesia (PCA) device; and is able to communicate meaningfully with the study staff.

    • Must voluntarily sign and date an informed consent form (ICF), approved by an Institutional Review Board (IRB), prior to the conduct of any study specific procedures.

    • Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.

    Exclusion Criteria:
    • Has known hypersensitivity to amide local anesthetics, opioids, bovine products or to inactive ingredients of the test article or reference product.

    • Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.

    • Concomitantly uses other amide local anesthetics.

    • Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).

    • Has used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.

    • Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days prior to Screening.

    • Has undergone major surgery within 3 months of the scheduled hysterectomy.

    • Requires the use of Seprafilm® or other absorbable adhesion barriers for the scheduled hysterectomy.

    • Requires any additional surgical procedures either related or unrelated to the abdominal hysterectomy during the same hospitalization (except for the specific allowed procedures noted in the Inclusion Criteria).

    • Is required to receive neuraxial (spinal or epidural) opioid analgesics during the surgery.

    • Has known or suspected history of alcohol or drug abuse or misuse within 3 years of Screening or evidence of tolerance or physical dependency on opioid analgesics or sedative hypnotic medications.

    • Has used opioids or tramadol on an extended daily basis (> 7 days) prior to surgery. Patients who, in the Investigator's opinion, are developing opioid tolerance are to be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Visions Clinical Research Boynton Beach Florida United States 33472

    Sponsors and Collaborators

    • Innocoll
    • Premier Research Group plc

    Investigators

    • Study Director: David Prior, Innocoll

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Innocoll
    ClinicalTrials.gov Identifier:
    NCT00749749
    Other Study ID Numbers:
    • INN-CB-005
    First Posted:
    Sep 9, 2008
    Last Update Posted:
    Nov 4, 2020
    Last Verified:
    Nov 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Innocoll
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Period Title: Overall Study
    STARTED 14 13
    COMPLETED 14 13
    NOT COMPLETED 0 0

    Baseline Characteristics

    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System Total
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg]) Total of all reporting groups
    Overall Participants 14 13 27
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    43.3
    (11.50)
    43.4
    (41.0)
    43.3
    (9.15)
    Sex: Female, Male (Count of Participants)
    Female
    14
    100%
    13
    100%
    27
    100%
    Male
    0
    0%
    0
    0%
    0
    0%
    Race (NIH/OMB) (Count of Participants)
    American Indian or Alaska Native
    0
    0%
    0
    0%
    0
    0%
    Asian
    1
    7.1%
    0
    0%
    1
    3.7%
    Native Hawaiian or Other Pacific Islander
    0
    0%
    0
    0%
    0
    0%
    Black or African American
    2
    14.3%
    5
    38.5%
    7
    25.9%
    White
    11
    78.6%
    8
    61.5%
    19
    70.4%
    More than one race
    0
    0%
    0
    0%
    0
    0%
    Unknown or Not Reported
    0
    0%
    0
    0%
    0
    0%

    Outcome Measures

    1. Primary Outcome
    Title Total Amount of Opioid Rescue Analgesia Used
    Description Higher value means worse outcome - Higher number reflects a need for more analgesia - For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. Measurement recorded in total Morphine Milligrams
    Time Frame 0 to 24 hours postoperatively

    Outcome Measure Data

    Analysis Population Description
    Intent-to-Treat Population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Mean (Standard Deviation) [Morphine Milligrams]
    46.85
    (21.57)
    67.03
    (32.416)
    2. Secondary Outcome
    Title Total Amount of Opioid Rescue Analgesia Used
    Description Higher score means worse outcome - Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.
    Time Frame 0 to 48 hours postoperatively

    Outcome Measure Data

    Analysis Population Description
    ITT population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Mean (Standard Deviation) [Morphine equivalents]
    55.43
    (22.770)
    74.85
    (35.381)
    3. Secondary Outcome
    Title The Total Amount of Opioid Rescue Analgesia Used
    Description Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.
    Time Frame 0 to 96 hours postoperatively

    Outcome Measure Data

    Analysis Population Description
    ITT Population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Mean (Standard Deviation) [Morphine equivalents]
    67.87
    (28.175)
    90.77
    (46.114)
    4. Secondary Outcome
    Title Total Use of Opioid Rescue Analgesia (mg) Over 0 to 72 Hours
    Description Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.
    Time Frame 0 to 72 Hours

    Outcome Measure Data

    Analysis Population Description
    ITT population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Mean (Standard Deviation) [Morphine equivalents]
    61.98
    (25.27)
    85.36
    (41.887)
    5. Secondary Outcome
    Title Time to First Use of Opioid Rescue Analgesia
    Description Higher score has a better outcome
    Time Frame 0 to 72 hours

    Outcome Measure Data

    Analysis Population Description
    Intent-to-Treat Population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Median (95% Confidence Interval) [Hours]
    0.78
    0.57
    6. Secondary Outcome
    Title VAS Pain Intensity Scores Over Time AT REST
    Description For the VAS assessment, patients measured their pain intensity at rest using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.
    Time Frame Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96

    Outcome Measure Data

    Analysis Population Description
    ITT population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Hour 1.0
    75.2
    (21.32)
    74.5
    (22.75)
    Hour 1.5
    66.3
    (24.96)
    66.5
    (28.65)
    Hour 2
    61.5
    (26.92)
    68.6
    (26.52)
    Hour 3
    52.2
    (21.71)
    60.9
    (29.85)
    Hour 6
    49.9
    (32.15)
    45.8
    (24.49)
    Hour 9
    38.1
    (29.37)
    35.8
    (24.48)
    Hour 12
    43.6
    (33.33)
    38.9
    (25.87)
    Hour 18
    44.5
    (29.46)
    50.7
    (30.59)
    Hour 24
    49.3
    (32.63)
    40.3
    (26.04)
    Hour 36
    47.0
    (32.11)
    27.8
    (20.27)
    Hour 48
    34.2
    (27.31)
    27.9
    (19.67)
    Hour 72
    27.4
    (24.79)
    34.6
    (30.00)
    Hour 96
    27.1
    (23.70)
    19.1
    (28.24)
    7. Secondary Outcome
    Title VAS (mm) Pain Intensity Scores Over Time (After Cough)
    Description For the VAS assessment, patients measured their pain intensity after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.
    Time Frame Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96

    Outcome Measure Data

    Analysis Population Description
    Intent-to-Treat Population
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    Measure Participants 14 13
    Hour 1
    84.4
    (21.41)
    86.1
    (21.72)
    Hour 1.5
    76.5
    (24.54)
    79.8
    (25.33)
    Hour 2.0
    73.8
    (26.25)
    84.6
    (24.19)
    Hour 3.0
    62.1
    (26.52)
    77.1
    (31.40)
    hour 6.0
    61.9
    (33.51)
    65.8
    (28.50)
    Hour 9.0
    51.5
    (33.07)
    52.5
    (28.08)
    Hour 12
    43.6
    (33.33)
    38.9
    (25.87)
    Hour 18
    44.5
    (29.46)
    50.7
    (30.59)
    Hour 24
    49.3
    (32.63)
    40.3
    (26.04)
    Hour 36
    47.0
    (32.11)
    27.8
    (20.27)
    Hour 48
    34.2
    (27.31)
    27.9
    (19.67)
    Hour 72
    27.4
    (24.79)
    34.6
    (30.00)
    Hour 96
    27.1
    (23.70)
    19.1
    (28.24)

    Adverse Events

    Time Frame Information regarding AEs was collected from the time of hospital admission through Day 30. Normal postoperative sequelae were not considered to be AEs unless they occurred in a more severe form, as judged by the Investigator. Information on AEs was also collected during the Day 8 and Day 30 follow-up calls.
    Adverse Event Reporting Description
    Arm/Group Title Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Arm/Group Description Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
    All Cause Mortality
    Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/14 (0%) 0/13 (0%)
    Serious Adverse Events
    Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/14 (0%) 0/13 (0%)
    Other (Not Including Serious) Adverse Events
    Bupivacaine Collagen Sponge ON-ON-Q PainBuster Post-op Pain Relief SystemQ System
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 7/14 (50%) 9/13 (69.2%)
    Gastrointestinal disorders
    Constipation 2/14 (14.3%) 2 0/13 (0%) 0
    Flatulence 2/14 (14.3%) 2 0/13 (0%) 0
    Nausea 1/14 (7.1%) 1 2/13 (15.4%) 2
    Vomiting 1/14 (7.1%) 1 1/13 (7.7%) 1
    Abdominal distension 0/14 (0%) 0 1/13 (7.7%) 1
    General disorders
    Pyrexia 1/14 (7.1%) 1 2/13 (15.4%) 2
    Oedema peripheral 0/14 (0%) 0 1/13 (7.7%) 1
    Chills 0/14 (0%) 0 1/13 (7.7%) 1
    Nervous system disorders
    Headache 2/14 (14.3%) 2 1/13 (7.7%) 1
    Skin and subcutaneous tissue disorders
    Rash 2/14 (14.3%) 2 0/13 (0%) 0

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Innocoll
    Organization Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management
    Phone 484-406-5211
    Email ctucker@innocoll.com
    Responsible Party:
    Innocoll
    ClinicalTrials.gov Identifier:
    NCT00749749
    Other Study ID Numbers:
    • INN-CB-005
    First Posted:
    Sep 9, 2008
    Last Update Posted:
    Nov 4, 2020
    Last Verified:
    Nov 1, 2020